FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809493612> ?p ?o ?g. }

• W2809493612 endingPage "802" @default.
• W2809493612 startingPage "793" @default.
• W2809493612 abstract "•Patients with normal on-treatment ALT after antiviral treatment had lower risk of hepatic events. •Adjusted hazard ratios for normal on-treatment ALT at 3, 6, 9 and 12 months were 0.61, 0.54, 0.53 and 0.50 respectively. •Similar findings were identified using AASLD, APASL or local laboratory criteria for normal ALT. Background & Aims Recent studies reveal that the rate of normal on-treatment alanine aminotransferase (ALT) appears different for different nucleos(t)ide analogues (NAs); yet its clinical significance is unclear. We aimed to evaluate the impact of normal on-treatment ALT during antiviral treatment with entecavir (ETV) or tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB). Methods A territory-wide cohort of patients with CHB who received ETV and/or TDF in 2005–2016 was identified. Serial on-treatment ALT levels were collected and analyzed. Normal on-treatment ALT (ALT-N) was defined as ALT <30 U/L in males and <19 U/L in females. The primary and secondary outcomes were composite hepatic events (including hepatocellular carcinoma) based on diagnostic codes. Patients with hepatic events before or during the first year of antiviral treatment or follow-up <1 year were excluded. Results A total of 21,182 patients with CHB (10,437 with and 10,745 without ALT-N at 12 months after antiviral treatment) were identified and followed for 4.0 ± 1.7 years. Patients with and without ALT-N differed in baseline ALT (58 vs. 61 U/L), hepatitis B virus DNA (4.9 vs. 5.1 log10 IU/ml) and cirrhosis status (8.8% vs. 10.5%). A total of 627 (3.0%) patients developed composite hepatic events. Compared to no ALT-N, ALT-N at 3, 6, 9 and 12 months reduced the risk of hepatic events, after adjustment for baseline ALT and other important covariates, with adjusted hazard ratios (95% CI) of 0.61 (0.49–0.77), 0.55 (0.45–0.67), 0.54 (0.44–0.65) and 0.51 (0.42–0.61) respectively (all p <0.001). The cumulative incidence (95% CI) of composite hepatic events at six years was 3.51% (3.06%-4.02%) in ALT-N and 5.70% (5.15%–6.32%) in the no ALT-N group (p <0.001). Conclusions Normal on-treatment ALT is associated with a lower risk of hepatic events in patients with CHB receiving NA treatment, translating into improved clinical outcomes in these patients. Lay summary We investigated 21,182 patients with chronic hepatitis B receiving antiviral treatment. Alanine aminotransferase is a laboratory marker of liver function, with raised levels indicating liver dysfunction and in severe cases hepatitis. Normal on-treatment alanine aminotransferase during the first year of treatment in patients with CHB is associated with a lower risk of hepatic events. Recent studies reveal that the rate of normal on-treatment alanine aminotransferase (ALT) appears different for different nucleos(t)ide analogues (NAs); yet its clinical significance is unclear. We aimed to evaluate the impact of normal on-treatment ALT during antiviral treatment with entecavir (ETV) or tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB). A territory-wide cohort of patients with CHB who received ETV and/or TDF in 2005–2016 was identified. Serial on-treatment ALT levels were collected and analyzed. Normal on-treatment ALT (ALT-N) was defined as ALT <30 U/L in males and <19 U/L in females. The primary and secondary outcomes were composite hepatic events (including hepatocellular carcinoma) based on diagnostic codes. Patients with hepatic events before or during the first year of antiviral treatment or follow-up <1 year were excluded. A total of 21,182 patients with CHB (10,437 with and 10,745 without ALT-N at 12 months after antiviral treatment) were identified and followed for 4.0 ± 1.7 years. Patients with and without ALT-N differed in baseline ALT (58 vs. 61 U/L), hepatitis B virus DNA (4.9 vs. 5.1 log10 IU/ml) and cirrhosis status (8.8% vs. 10.5%). A total of 627 (3.0%) patients developed composite hepatic events. Compared to no ALT-N, ALT-N at 3, 6, 9 and 12 months reduced the risk of hepatic events, after adjustment for baseline ALT and other important covariates, with adjusted hazard ratios (95% CI) of 0.61 (0.49–0.77), 0.55 (0.45–0.67), 0.54 (0.44–0.65) and 0.51 (0.42–0.61) respectively (all p <0.001). The cumulative incidence (95% CI) of composite hepatic events at six years was 3.51% (3.06%-4.02%) in ALT-N and 5.70% (5.15%–6.32%) in the no ALT-N group (p <0.001). Normal on-treatment ALT is associated with a lower risk of hepatic events in patients with CHB receiving NA treatment, translating into improved clinical outcomes in these patients." @default.
• W2809493612 created "2018-06-29" @default.
• W2809493612 creator A5009718905 @default.
• W2809493612 creator A5026611066 @default.
• W2809493612 creator A5029738510 @default.
• W2809493612 creator A5046528197 @default.
• W2809493612 creator A5080796258 @default.
• W2809493612 creator A5087968813 @default.
• W2809493612 creator A5090173649 @default.
• W2809493612 date "2018-10-01" @default.
• W2809493612 modified "2023-10-18" @default.
• W2809493612 title "Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B" @default.
• W2809493612 cites W1965074477 @default.
• W2809493612 cites W1973978383 @default.
• W2809493612 cites W2001497311 @default.
• W2809493612 cites W2007065415 @default.
• W2809493612 cites W2015148330 @default.
• W2809493612 cites W2044395825 @default.
• W2809493612 cites W2049416085 @default.
• W2809493612 cites W2085428347 @default.
• W2809493612 cites W2090738619 @default.
• W2809493612 cites W2114907507 @default.
• W2809493612 cites W2161385398 @default.
• W2809493612 cites W2162566260 @default.
• W2809493612 cites W2173698250 @default.
• W2809493612 cites W2174723704 @default.
• W2809493612 cites W2297828361 @default.
• W2809493612 cites W2521726183 @default.
• W2809493612 cites W2525461620 @default.
• W2809493612 cites W2605785536 @default.
• W2809493612 cites W2612496400 @default.
• W2809493612 cites W2622524891 @default.
• W2809493612 cites W2713151051 @default.
• W2809493612 cites W2758370600 @default.
• W2809493612 cites W3023734274 @default.
• W2809493612 cites W4239743462 @default.
• W2809493612 doi "https://doi.org/10.1016/j.jhep.2018.05.009" @default.
• W2809493612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29758335" @default.
• W2809493612 hasPublicationYear "2018" @default.
• W2809493612 type Work @default.
• W2809493612 sameAs 2809493612 @default.
• W2809493612 citedByCount "74" @default.
• W2809493612 countsByYear W28094936122018 @default.
• W2809493612 countsByYear W28094936122019 @default.
• W2809493612 countsByYear W28094936122020 @default.
• W2809493612 countsByYear W28094936122021 @default.
• W2809493612 countsByYear W28094936122022 @default.
• W2809493612 countsByYear W28094936122023 @default.
• W2809493612 crossrefType "journal-article" @default.
• W2809493612 hasAuthorship W2809493612A5009718905 @default.
• W2809493612 hasAuthorship W2809493612A5026611066 @default.
• W2809493612 hasAuthorship W2809493612A5029738510 @default.
• W2809493612 hasAuthorship W2809493612A5046528197 @default.
• W2809493612 hasAuthorship W2809493612A5080796258 @default.
• W2809493612 hasAuthorship W2809493612A5087968813 @default.
• W2809493612 hasAuthorship W2809493612A5090173649 @default.
• W2809493612 hasConcept C126322002 @default.
• W2809493612 hasConcept C203014093 @default.
• W2809493612 hasConcept C207103383 @default.
• W2809493612 hasConcept C2522874641 @default.
• W2809493612 hasConcept C2776175608 @default.
• W2809493612 hasConcept C2777382497 @default.
• W2809493612 hasConcept C2777869810 @default.
• W2809493612 hasConcept C2778019345 @default.
• W2809493612 hasConcept C2778606649 @default.
• W2809493612 hasConcept C2992872382 @default.
• W2809493612 hasConcept C3020491458 @default.
• W2809493612 hasConcept C3020505244 @default.
• W2809493612 hasConcept C44249647 @default.
• W2809493612 hasConcept C71924100 @default.
• W2809493612 hasConcept C90924648 @default.
• W2809493612 hasConceptScore W2809493612C126322002 @default.
• W2809493612 hasConceptScore W2809493612C203014093 @default.
• W2809493612 hasConceptScore W2809493612C207103383 @default.
• W2809493612 hasConceptScore W2809493612C2522874641 @default.
• W2809493612 hasConceptScore W2809493612C2776175608 @default.
• W2809493612 hasConceptScore W2809493612C2777382497 @default.
• W2809493612 hasConceptScore W2809493612C2777869810 @default.
• W2809493612 hasConceptScore W2809493612C2778019345 @default.
• W2809493612 hasConceptScore W2809493612C2778606649 @default.
• W2809493612 hasConceptScore W2809493612C2992872382 @default.
• W2809493612 hasConceptScore W2809493612C3020491458 @default.
• W2809493612 hasConceptScore W2809493612C3020505244 @default.
• W2809493612 hasConceptScore W2809493612C44249647 @default.
• W2809493612 hasConceptScore W2809493612C71924100 @default.
• W2809493612 hasConceptScore W2809493612C90924648 @default.
• W2809493612 hasIssue "4" @default.
• W2809493612 hasLocation W28094936121 @default.
• W2809493612 hasLocation W28094936122 @default.
• W2809493612 hasOpenAccess W2809493612 @default.
• W2809493612 hasPrimaryLocation W28094936121 @default.
• W2809493612 hasRelatedWork W1268527382 @default.
• W2809493612 hasRelatedWork W1979162667 @default.
• W2809493612 hasRelatedWork W1999299204 @default.
• W2809493612 hasRelatedWork W2067818705 @default.
• W2809493612 hasRelatedWork W2085967240 @default.
• W2809493612 hasRelatedWork W2162314464 @default.
• W2809493612 hasRelatedWork W2361664698 @default.

• next